Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582568 · ClinicalTrials.gov registry record
EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment
A clinical trial, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01582568: Clinical Trial study, sponsored by Baylor College of Medicine.
NCT01582568 is a clinical trial that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582568 was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess perianal and perirectal fistula healing (complete closure) based on endoscopic ultrasound (EUS) evaluation at 3 months and by PDAI (Pouchitis Disease Activity Index) and Fistula Drainage assessment by 6 months, showing no fistula (new or recurrence) in treatment of Crohn's' disease patient with Certolizumab (Cimzia).
Primary Outcome
The primary objective of this study is to assess perianal and perirectal fistula healing (complete closure) based on endoscopic ultrasound (EUS) evaluation at 3 months and by PDAI (Pouchitis Disease Activity Index) and Fistula Drainage assessment by 6 months, showing no fistula (new or recurrence) on treatment of Certolizumab (Cimzia) in Crohn's's disease patient s.
Interventions
- DRUG Certolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-03 |
Why NCT01582568 stopped before completion
NCT01582568 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab is the first listed.
NCT01582568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01582568 about?
NCT01582568 is a clinical study titled "EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment". The primary objective of this study is to assess perianal and perirectal fistula healing (complete closure) based on endoscopic ultrasound (EUS) evaluation at 3 months and by PDAI (Pouchitis Disease Activity Index) and Fistula Drainage assessment by 6 months, showing no fistula (new or recurrence) i...
What is the current status of trial NCT01582568?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2011-06. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01582568?
The interventions under investigation include: Certolizumab (DRUG).
Who is sponsoring clinical trial NCT01582568?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia